Article

New antihistamine eye drop controls itchy eyes

Schering-Plough Corp. has launched an antihistamine eye drop (Claritin Eye) designed to control the itch of allergy eyes for up to 12 hours.

Kenilworth, NJ

-Schering-Plough Corp. has launched an antihistamine eye drop (Claritin Eye) designed to control the itch of allergy eyes for up to 12 hours.

“Itchy eyes are an extremely bothersome symptom for allergy sufferers and can be caused by indoor or outdoor allergens, such as dust, pet dander, mold, or pollen. [The antihistamine eye drop] relieves the itch at the source by blocking the histamine that causes itchy eyes,” said John O’Mullane, PhD, group vice president, research and development, Schering-Plough Consumer HealthCare.

The makers of the drop have launched a national advertising campaign to support the introduction of the product, according to a prepared statement. In addition, the brand’s newly launched Facebook page,

www.facebook.com/claritineye

, offers facts and tips for those who experience allergies. The page also features an “eye makeover” tool that allows consumers to upload photographs and use the application to clear the red eye in their pictures.

The drop is available without a prescription and can be found in most food, drug, and mass retailers.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.